Jonathan Allan sold $286k of STOK
GENERAL COUNSEL & CORP SEC at Stoke Therapeutics, Inc.. 8,895 shares at an average of $32.14, traded Mar 17, 2026, filed Mar 19, 2026.
Score components
- +15RoleOfficer
- +14Trade size$286k at market
- +5Share of holdings soldSold 24% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001966716-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 17, 2026 | SOpen-market sale Common Stock | -2,476 | $32.74 | $81k | 35,255 | Mar 19, 2026 |
| Mar 17, 2026 | SOpen-market sale Common Stock | -1,791 | $33.38 | $60k | 33,464 | Mar 19, 2026 |
| Mar 18, 2026 | SOpen-market sale Common Stock | -4,222 | $31.28 | $132k | 29,242 | Mar 19, 2026 |
| Mar 18, 2026 | SOpen-market sale Common Stock | -334 | $31.79 | $11k | 28,908 | Mar 19, 2026 |
| Mar 18, 2026 | SOpen-market sale Common Stock | -72 | $32.85 | $2,365 | 28,836 | Mar 19, 2026 |
Related signals
Other insiders at Stoke Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $17k 627 shares | -3% | |
| 8Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $27k 1,051 shares | -5% | |
| 11Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $170k 5,545 shares | -22% | |
| 19Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $313k 9,293 shares | -32% | |
| 31Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $128k 3,978 shares | -25% | |
| 32Weak | Stoke Therapeutics, Inc. | Edward M. Kaye MD CEO | $433k 13,430 shares | -21% | |
| 19Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $306k 9,803 shares | -38% | |
| 17Weak | Stoke Therapeutics, Inc. | Edward M. Kaye MD CEO | $467k 15,001 shares | -19% | |
| 11Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $167k 5,358 shares | -21% | |
| 31Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $138k 4,576 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.